Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery
Matthew R. Wilson(Beatson West of Scotland Cancer Centre), Pam McKay(Beatson West of Scotland Cancer Centre), Kim Linton(The Christie NHS Foundation Trust), Johnathon Elliot(The Christie Hospital), Kate Cwynarski(Royal London Hospital), Cheuk-Kie Cheung(Oxford University Hospitals NHS Trust), Matthew J. Ahearne(University of Leicester), Jeremy Schofield(University of Liverpool), Nicolás Martínez‐Calle(Nottingham University Hospitals NHS Trust), Jeffery Smith(University of Liverpool), Toby A. Eyre(Oxford University Hospitals NHS Trust), Thomas Creasey(Newcastle upon Tyne Hospitals NHS Foundation Trust), Fiona Miall(University Hospitals of Leicester NHS Trust), Jahanzaib Khwaja(University College Hospital), Katrina Parsons(Beatson West of Scotland Cancer Centre), Christopher P. Fox(University of Nottingham), Almurtadha Mula kh(University Hospital Southampton NHS Foundation Trust), Nimish Shah(National Health Service), Gavin Preston(University of Leeds), Matthew A. Timmins(University Hospitals of Leicester NHS Trust)
Cited by 54
Related Papers
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2023|213